{"transactions":[{"id":721196,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-07-01T20:30:08.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":268,"price":11.15,"value":2988.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2026 through June 30, 2026.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026."}],"balance_after":416742,"source":{"system":"sec-edgar","filing":"0001654435-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000165443526000003/primarydocument.xml","form_type":"4"}},{"id":943194,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-08T21:21:49.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":1,"price":10.99,"value":10.99,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025."}],"balance_after":416474,"source":{"system":"sec-edgar","filing":"0001654435-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000165443526000001/primarydocument.xml","form_type":"5"}},{"id":1097822,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-07-01T20:19:41.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":833,"price":15.13,"value":12603.29,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2025 through June 30, 2025.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025."}],"balance_after":416473,"source":{"system":"sec-edgar","filing":"0001562180-25-005187","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025005187/primarydocument.xml","form_type":"4"}},{"id":1314719,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-01-03T21:04:05.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates."}],"balance_after":415640,"source":{"system":"sec-edgar","filing":"0001562180-25-000065","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025000065/primarydocument.xml","form_type":"4"}},{"id":1314718,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-01-03T21:04:05.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":412,"price":14.748,"value":6076.176,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024."}],"balance_after":15640,"source":{"system":"sec-edgar","filing":"0001562180-25-000065","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218025000065/primarydocument.xml","form_type":"4"}},{"id":1439624,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2024-08-06T20:19:58.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":1239,"price":12.24,"value":15165.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2024 through June 30, 2024.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024."}],"balance_after":15228,"source":{"system":"sec-edgar","filing":"0001562180-24-006041","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024006041/primarydocument.xml","form_type":"4"}},{"id":1833828,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-07-06T20:12:10.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":367,"price":35.28,"value":12947.76,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January1, 2023 through June 30, 2023.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023."}],"balance_after":13989,"source":{"system":"sec-edgar","filing":"0001562180-23-005755","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023005755/primarydocument.xml","form_type":"4"}},{"id":2058825,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":7.15,"expiration_date":"2027-02-22","underlying":"Ordinary Shares","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058824,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.46,"expiration_date":"2026-02-24","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058823,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":39,"price":62.305,"value":2429.895,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"In accordance with the issuer's Employee Share Purchase Plan, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022."}],"balance_after":13622,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058822,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":187500,"price":108,"value":20250000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."}],"balance_after":13583,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058821,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":187500,"price":7.15,"value":1340625.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."}],"balance_after":201083,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058820,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":500,"price":119.987,"value":59993.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 500 shares in multiple trades at prices ranging from $119.98 to $120.00.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13583,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058819,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":1344,"price":119.3493,"value":160405.4592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,344 shares in multiple trades at prices ranging from $118.95 to $119.84.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":14083,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058818,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":2123,"price":118.4714,"value":251514.7822,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,123 shares in multiple trades at prices ranging from $117.91 to $118.90.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":15427,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058817,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":999,"price":117.0111,"value":116894.0889,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 999 shares in multiple trades at prices ranging from $116.85 to $117.82.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":17550,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058816,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":1395,"price":116.0618,"value":161906.211,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,395 shares in multiple trades at prices ranging from $115.79 to $116.45.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":18549,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058815,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":3702,"price":115.2113,"value":426512.2326,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,702 shares in multiple trades at prices ranging from $114.79 to $115.78.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":19944,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058814,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":4568,"price":114.3524,"value":522361.7632,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,568 shares in multiple trades at prices ranging from $113.76 to $114.75.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23646,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058813,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":2000,"price":112.8632,"value":225726.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,000 shares in multiple trades at prices ranging from $112.29 to $113.26.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":28214,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058812,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":8369,"price":111.2338,"value":930915.6722,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 8,369 shares in multiple trades at prices ranging from $111.00 to $111.97.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":30214,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2058811,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-09T23:18:44.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":25000,"price":11.46,"value":286500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."}],"balance_after":38583,"source":{"system":"sec-edgar","filing":"0001645113-23-000007","document":"wf-form4_167330630889022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000007/wf-form4_167330630889022.xml","form_type":"4"}},{"id":2210746,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-07T21:48:11.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":276,"price":59.075,"value":16304.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2022 through June 30, 2022.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022."}],"balance_after":13583,"source":{"system":"sec-edgar","filing":"0001645113-22-000062","document":"wf-form4_165723047506853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000062/wf-form4_165723047506853.xml","form_type":"4"}},{"id":2347780,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-03-07T23:22:15.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":13470,"price":80.59,"value":1085547.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Options to buy 13,470 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates."}],"balance_after":13470,"derivative":{"exercise_price":80.59,"exercise_date":"2023-03-01","expiration_date":"2032-02-29","underlying":"Ordinary Shares","underlying_shares":13470},"source":{"system":"sec-edgar","filing":"0001645113-22-000019","document":"wf-form4_164669531950813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000019/wf-form4_164669531950813.xml","form_type":"4"}},{"id":2436838,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-12T22:31:49.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":31,"price":63.818,"value":1978.358,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2021 through December 31, 2021.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021."}],"balance_after":13307,"source":{"system":"sec-edgar","filing":"0001645113-22-000004","document":"wf-form4_164202669529935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000004/wf-form4_164202669529935.xml","form_type":"4"}},{"id":2493237,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-29T21:48:17.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":104,"price":96.5,"value":10036.0,"ownership":{"direct":true},"balance_after":13276,"source":{"system":"sec-edgar","filing":"0001645113-21-000116","document":"wf-form4_163822248140323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000116/wf-form4_163822248140323.xml","form_type":"4"}},{"id":2493236,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-29T21:48:17.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":1000,"price":103.37,"value":103370.0,"ownership":{"direct":true},"balance_after":13172,"source":{"system":"sec-edgar","filing":"0001645113-21-000116","document":"wf-form4_163822248140323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000116/wf-form4_163822248140323.xml","form_type":"4"}},{"id":2493235,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-11-29T21:48:17.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":3870,"price":102.36,"value":396133.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 26, 2021, Mr. Danziger purchased 3,870 shares in multiple trades at prices ranging from $102.00 to $102.60.  The price reported above reflects the weighted average purchase price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":12172,"source":{"system":"sec-edgar","filing":"0001645113-21-000116","document":"wf-form4_163822248140323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000116/wf-form4_163822248140323.xml","form_type":"4"}},{"id":2638084,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-07-08T21:31:12.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":118,"price":137.122,"value":16180.396,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2021 through June 30, 2021.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021."}],"balance_after":8302,"source":{"system":"sec-edgar","filing":"0001645113-21-000084","document":"wf-form4_162577981023454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000084/wf-form4_162577981023454.xml","form_type":"4"}},{"id":2748616,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-15T22:01:42.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":97973,"price":196.3431,"value":19236322.5363,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amended total to correct prior mathematical error."}],"balance_after":8184,"source":{"system":"sec-edgar","filing":"0001645113-21-000055","document":"wf-form4_161852408765067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000055/wf-form4_161852408765067.xml","form_type":"4"}},{"id":2820162,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T21:17:12.000Z","date":"2021-02-27","kind":"exercise","acquired":false,"shares":9259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2021-02-27","underlying":"Ordinary Shares","underlying_shares":9259},"source":{"system":"sec-edgar","filing":"0001645113-21-000024","document":"wf-form4_161471980303632.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000024/wf-form4_161471980303632.xml","form_type":"4"}},{"id":2820161,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:17:12.000Z","date":"2021-02-27","kind":"exercise","acquired":true,"shares":9259,"price":149.1,"value":1380516.9,"ownership":{"direct":true},"balance_after":206944,"source":{"system":"sec-edgar","filing":"0001645113-21-000024","document":"wf-form4_161471980303632.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000024/wf-form4_161471980303632.xml","form_type":"4"}},{"id":2912222,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2021-01-08T21:30:34.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":53,"price":50.669,"value":2685.457,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2020 through December 31, 2020.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2020."}],"balance_after":197685,"source":{"system":"sec-edgar","filing":"0001645113-21-000001","document":"wf-form4_161014142054692.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000001/wf-form4_161014142054692.xml","form_type":"4"}},{"id":2934679,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":103955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F24","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":22,"expiration_date":"2025-10-01","underlying":"Ordinary Shares","underlying_shares":103955},"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934678,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":103955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F24","text":"Fully vested as of the date hereof."}],"balance_after":103955,"derivative":{"exercise_price":22,"expiration_date":"2025-10-01","underlying":"Ordinary Shares","underlying_shares":103955},"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934677,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":400,"price":166.079,"value":66431.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F23","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 400 shares in multiple trades at prices ranging from $165.97 to $166.12.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":197632,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934676,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":971,"price":164.959,"value":160175.189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F22","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 971 shares in multiple trades at prices ranging from $164.52 to $165.35.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":198032,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934675,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":536,"price":163.348,"value":87554.528,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F21","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 536 shares in multiple trades at prices ranging from $163.25 to $163.60.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":199003,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934674,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":1700,"price":162.353,"value":276000.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F20","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,700 shares in multiple trades at prices ranging from $161.81 to $162.80.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":199539,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934673,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":4014,"price":161.106,"value":646679.484,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,014 shares in multiple trades at prices ranging from $160.78 to $161.76.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":201239,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934672,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":11686,"price":160.27,"value":1872915.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 11,686 shares in multiple trades at prices ranging from $159.76 to $160.72.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":205253,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934671,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":4790,"price":159.27,"value":762903.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,790 shares in multiple trades at prices ranging from $158.72 to $159.63.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":216939,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934670,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":10077,"price":158.064,"value":1592810.928,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 10,077 shares in multiple trades at prices ranging from $157.64 to $158.60.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":221729,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934669,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":23601,"price":157.007,"value":3705522.207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 23,601 shares in multiple trades at prices ranging from $156.63 to $157.61.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":231806,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934668,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":24973,"price":156.083,"value":3897860.759,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 24,973 shares in multiple trades at prices ranging from $155.63 to $156.62.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":255407,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934667,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":21207,"price":155.232,"value":3292005.024,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 21,207 shares in multiple trades at prices ranging from $154.63 to $155.60.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":280380,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934666,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":103955,"price":22,"value":2287010.0,"ownership":{"direct":true},"balance_after":301587,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934665,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":200,"price":166.172,"value":33234.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 200 shares in multiple trades at prices ranging from $165.97 to $166.38.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":197632,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934664,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":700,"price":165.383,"value":115768.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 700 shares in multiple trades at prices ranging from $164.90 to $165.75.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":197832,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934663,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":500,"price":164.109,"value":82054.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 500 shares in multiple trades at prices ranging from $163.82 to $164.53.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":198532,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934662,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":1300,"price":162.969,"value":211859.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,300 shares in multiple trades at prices ranging from $162.80 to $163.37.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":199032,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934661,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":1426,"price":162.173,"value":231258.698,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,426 shares in multiple trades at prices ranging from $161.77 to $162.39.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":200332,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934660,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":3500,"price":160.994,"value":563479.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,500 shares in multiple trades at prices ranging from $160.70 to $161.38.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":201758,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934659,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":12092,"price":160.25,"value":1937743.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 12,092 shares in multiple trades at prices ranging from $159.68 to $160.68.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":205258,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934658,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":4500,"price":159.323,"value":716953.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,500 shares in multiple trades at prices ranging from $158.68 to $159.65.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":217350,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934657,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":9183,"price":158.094,"value":1451777.202,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 9,183 shares in multiple trades at prices ranging from $157.64 to $158.52.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":221850,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934656,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":24656,"price":157.037,"value":3871904.272,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 24,656 shares in multiple trades at prices ranging from $156.63 to $157.60.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":231033,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934655,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":24286,"price":156.091,"value":3790826.026,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 24,286 shares in multiple trades at prices ranging from $155.63 to $156.62.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":255689,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934654,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"sale","acquired":false,"shares":21612,"price":155.24,"value":3355046.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 21,612 shares in multiple trades at prices ranging from $154.63 to $155.61.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":279975,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":2934653,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-22T23:37:37.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":103955,"price":22,"value":2287010.0,"ownership":{"direct":true},"balance_after":301587,"source":{"system":"sec-edgar","filing":"0001628280-20-017710","document":"wf-form4_160868024119764.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000162828020017710/wf-form4_160868024119764.xml","form_type":"4"}},{"id":3028478,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-17T20:32:54.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date hereof."}],"balance_after":207910,"derivative":{"exercise_price":22,"expiration_date":"2025-10-01","underlying":"Ordinary Shares","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001645113-20-000138","document":"wf-form4_160037475873784.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000138/wf-form4_160037475873784.xml","form_type":"4"}},{"id":3028477,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-17T20:32:54.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":103000,"price":99,"value":10197000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."}],"balance_after":197632,"source":{"system":"sec-edgar","filing":"0001645113-20-000138","document":"wf-form4_160037475873784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000138/wf-form4_160037475873784.xml","form_type":"4"}},{"id":3028476,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-17T20:32:54.000Z","date":"2020-09-15","kind":"exercise","acquired":true,"shares":103000,"price":22,"value":2266000.0,"ownership":{"direct":true},"balance_after":300632,"source":{"system":"sec-edgar","filing":"0001645113-20-000138","document":"wf-form4_160037475873784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000138/wf-form4_160037475873784.xml","form_type":"4"}},{"id":3086567,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-07-08T20:18:48.000Z","date":"2020-07-07","kind":"grant","acquired":true,"shares":284,"price":50.405,"value":14315.02,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2020 through June 30, 2020.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020."}],"balance_after":197632,"source":{"system":"sec-edgar","filing":"0001645113-20-000092","document":"wf-form4_159423951502640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000092/wf-form4_159423951502640.xml","form_type":"4"}},{"id":3238228,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2020-03-02T22:15:55.000Z","date":"2020-02-27","kind":"exercise","acquired":false,"shares":9259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Fully vested as of the date hereof."}],"balance_after":9259,"derivative":{"exercise_price":0,"exercise_date":"2020-02-27","underlying":"Ordinary Shares","underlying_shares":9259},"source":{"system":"sec-edgar","filing":"0001645113-20-000032","document":"wf-form4_158318733739747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000032/wf-form4_158318733739747.xml","form_type":"4"}},{"id":3238227,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-03-02T22:15:55.000Z","date":"2020-02-27","kind":"exercise","acquired":true,"shares":9259,"price":79.45,"value":735627.55,"ownership":{"direct":true},"balance_after":197348,"source":{"system":"sec-edgar","filing":"0001645113-20-000032","document":"wf-form4_158318733739747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000032/wf-form4_158318733739747.xml","form_type":"4"}},{"id":3246385,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-26T22:19:52.000Z","date":"2020-02-24","kind":"exercise","acquired":true,"shares":53333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2020-02-22","underlying":"Ordinary Shares","underlying_shares":53333},"source":{"system":"sec-edgar","filing":"0001645113-20-000016","document":"wf-form4_158275557536813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000016/wf-form4_158275557536813.xml","form_type":"4"}},{"id":3246384,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Share Units","published_at":"2020-02-26T22:19:52.000Z","date":"2020-02-24","kind":"exercise","acquired":true,"shares":53333,"price":88.26,"value":4707170.58,"ownership":{"direct":true},"balance_after":188089,"source":{"system":"sec-edgar","filing":"0001645113-20-000016","document":"wf-form4_158275557536813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000016/wf-form4_158275557536813.xml","form_type":"4"}},{"id":3312576,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-01-13T21:11:17.000Z","date":"2020-01-08","kind":"grant","acquired":true,"shares":155,"price":52.581,"value":8150.055,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2019 through December 31, 2019.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2019."}],"balance_after":134756,"source":{"system":"sec-edgar","filing":"0001645113-20-000006","document":"wf-form4_157894985929754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000006/wf-form4_157894985929754.xml","form_type":"4"}},{"id":3358935,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-11-26T21:28:17.000Z","date":"2019-11-25","kind":"exercise","acquired":false,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date hereof."}],"balance_after":310910,"derivative":{"exercise_price":22,"expiration_date":"2025-10-01","underlying":"Ordinary Shares","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001645113-19-000014","document":"wf-form4_157480367954289.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511319000014/wf-form4_157480367954289.xml","form_type":"4"}},{"id":3358934,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-11-26T21:28:17.000Z","date":"2019-11-25","kind":"sale","acquired":false,"shares":103000,"price":95,"value":9785000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."}],"balance_after":134601,"source":{"system":"sec-edgar","filing":"0001645113-19-000014","document":"wf-form4_157480367954289.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511319000014/wf-form4_157480367954289.xml","form_type":"4"}},{"id":3358933,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-11-26T21:28:17.000Z","date":"2019-11-25","kind":"exercise","acquired":true,"shares":103000,"price":22,"value":2266000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger."}],"balance_after":237601,"source":{"system":"sec-edgar","filing":"0001645113-19-000014","document":"wf-form4_157480367954289.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511319000014/wf-form4_157480367954289.xml","form_type":"4"}},{"id":3425009,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-09-03T20:24:11.000Z","date":"2019-08-29","kind":"sale","acquired":false,"shares":500,"price":92,"value":46000.0,"ownership":{"direct":true},"balance_after":134601,"source":{"system":"sec-edgar","filing":"0001209191-19-047965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119047965/doc4.xml","form_type":"4"}},{"id":3425008,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-09-03T20:24:11.000Z","date":"2019-08-29","kind":"sale","acquired":false,"shares":65768,"price":91.604,"value":6024611.872,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 29, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 65,768 shares in multiple trades at prices ranging from $91.00 to $91.99.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":135101,"source":{"system":"sec-edgar","filing":"0001209191-19-047965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119047965/doc4.xml","form_type":"4"}},{"id":3425007,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-09-03T20:24:11.000Z","date":"2019-08-29","kind":"sale","acquired":false,"shares":57913,"price":90.577,"value":5245585.801,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 29, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 57,913 shares in multiple trades at prices ranging from $90.00 to $90.995.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":200869,"source":{"system":"sec-edgar","filing":"0001209191-19-047965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119047965/doc4.xml","form_type":"4"}},{"id":3465231,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-07-09T20:22:14.000Z","date":"2019-07-05","kind":"grant","acquired":true,"shares":471,"price":27.812,"value":13099.452,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2019 through June 30, 2019.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2019."}],"balance_after":258782,"source":{"system":"sec-edgar","filing":"0001209191-19-041555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119041555/doc4.xml","form_type":"4"}},{"id":3471301,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-07-02T20:12:01.000Z","date":"2019-06-28","kind":"exercise","acquired":false,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and currently exercisable as of the date hereof."}],"balance_after":187500,"derivative":{"exercise_price":7.15,"expiration_date":"2027-02-21","underlying":"Ordinary Shares","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001209191-19-040204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119040204/doc4.xml","form_type":"4"}},{"id":3471300,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-07-02T20:12:01.000Z","date":"2019-06-28","kind":"sale","acquired":false,"shares":187500,"price":62.15,"value":11653125.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":258311,"source":{"system":"sec-edgar","filing":"0001209191-19-040204","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119040204/doc4.xml","form_type":"4"}},{"id":3471299,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-07-02T20:12:01.000Z","date":"2019-06-28","kind":"exercise","acquired":true,"shares":187500,"price":7.15,"value":1340625.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":445811,"source":{"system":"sec-edgar","filing":"0001209191-19-040204","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119040204/doc4.xml","form_type":"4"}},{"id":3481440,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-06-21T20:03:16.000Z","date":"2019-06-19","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and currently exercisable as of the date hereof."}],"balance_after":25000,"derivative":{"exercise_price":11.46,"expiration_date":"2026-02-24","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-038449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119038449/doc4.xml","form_type":"4"}},{"id":3481439,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-21T20:03:16.000Z","date":"2019-06-19","kind":"sale","acquired":false,"shares":25000,"price":61.46,"value":1536500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":258311,"source":{"system":"sec-edgar","filing":"0001209191-19-038449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119038449/doc4.xml","form_type":"4"}},{"id":3481438,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-21T20:03:16.000Z","date":"2019-06-19","kind":"exercise","acquired":true,"shares":25000,"price":11.46,"value":286500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":283311,"source":{"system":"sec-edgar","filing":"0001209191-19-038449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119038449/doc4.xml","form_type":"4"}},{"id":3484257,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-06-19T20:16:31.000Z","date":"2019-06-18","kind":"exercise","acquired":false,"shares":190338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested and currently exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":14.37,"expiration_date":"2025-02-23","underlying":"Ordinary Shares","underlying_shares":190338},"source":{"system":"sec-edgar","filing":"0001209191-19-037997","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119037997/doc4.xml","form_type":"4"}},{"id":3484256,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-19T20:16:31.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":190338,"price":59.37,"value":11300367.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":258311,"source":{"system":"sec-edgar","filing":"0001209191-19-037997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119037997/doc4.xml","form_type":"4"}},{"id":3484255,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-19T20:16:31.000Z","date":"2019-06-18","kind":"exercise","acquired":true,"shares":190338,"price":14.37,"value":2735157.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":448649,"source":{"system":"sec-edgar","filing":"0001209191-19-037997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119037997/doc4.xml","form_type":"4"}},{"id":3491414,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":30436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested and currently exercisable as of the date hereof."}],"balance_after":190338,"derivative":{"exercise_price":14.37,"expiration_date":"2025-02-23","underlying":"Ordinary Shares","underlying_shares":30436},"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491413,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-11","kind":"exercise","acquired":false,"shares":16835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested and currently exercisable as of the date hereof."}],"balance_after":220774,"derivative":{"exercise_price":14.37,"expiration_date":"2025-02-23","underlying":"Ordinary Shares","underlying_shares":16835},"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491412,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":18203,"price":55.735,"value":1014544.205,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On June 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 18,203 shares in multiple trades at prices ranging from $55.40 to $56.10.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":258311,"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491411,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":12233,"price":54.886,"value":671420.438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On June 12, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 12,233 shares in multiple trades at prices ranging from $54.39 to $55.38.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":276514,"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491410,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":30436,"price":14.37,"value":437365.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":288747,"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491409,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-11","kind":"sale","acquired":false,"shares":850,"price":55.425,"value":47111.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On June 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 850 shares in multiple trades at prices ranging from $55.41 to $55.45.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":258311,"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491408,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-11","kind":"sale","acquired":false,"shares":15985,"price":54.71,"value":874539.35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 11, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 15,985 shares in multiple trades at prices ranging from $54.37 to $55.35.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":259161,"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3491407,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-13T20:16:00.000Z","date":"2019-06-11","kind":"exercise","acquired":true,"shares":16835,"price":14.37,"value":241918.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger."}],"balance_after":275146,"source":{"system":"sec-edgar","filing":"0001209191-19-036764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119036764/doc4.xml","form_type":"4"}},{"id":3531600,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-05-10T20:10:42.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to buy 35,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Danziger has been continuously employed by the Company through May 8, 2022."}],"balance_after":35000,"derivative":{"exercise_price":47.56,"expiration_date":"2029-05-08","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-028873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119028873/doc4.xml","form_type":"4"}},{"id":3531599,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-05-10T20:10:42.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":115060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to buy 115,060 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Danziger has been continuously employed by the Company through May 8, 2022."}],"balance_after":115060,"derivative":{"exercise_price":47.56,"expiration_date":"2029-05-08","underlying":"Ordinary Shares","underlying_shares":115060},"source":{"system":"sec-edgar","filing":"0001209191-19-028873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119028873/doc4.xml","form_type":"4"}},{"id":3578424,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-03-26T20:07:02.000Z","date":"2019-03-22","kind":"grant","acquired":true,"shares":44953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to buy 44,953 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates."}],"balance_after":44953,"derivative":{"exercise_price":47.04,"expiration_date":"2029-03-21","underlying":"Ordinary Shares","underlying_shares":44953},"source":{"system":"sec-edgar","filing":"0001209191-19-021304","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119021304/doc4.xml","form_type":"4"}},{"id":3578423,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Share Units","published_at":"2019-03-26T20:07:02.000Z","date":"2019-03-22","kind":"grant","acquired":true,"shares":24554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates."}],"balance_after":258311,"source":{"system":"sec-edgar","filing":"0001209191-19-021304","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119021304/doc4.xml","form_type":"4"}},{"id":3608429,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2019-03-06T21:17:39.000Z","date":"2019-03-04","kind":"exercise","acquired":false,"shares":16268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and currently exercisable as of the date hereof."}],"balance_after":237609,"derivative":{"exercise_price":14.37,"expiration_date":"2025-02-23","underlying":"Ordinary Shares","underlying_shares":16268},"source":{"system":"sec-edgar","filing":"0001209191-19-017328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119017328/doc4.xml","form_type":"4"}},{"id":3608428,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-03-06T21:17:39.000Z","date":"2019-03-04","kind":"sale","acquired":false,"shares":6441,"price":56.512,"value":363993.792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,441 shares in multiple trades at prices ranging from $56.39 to $56.62.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":233757,"source":{"system":"sec-edgar","filing":"0001209191-19-017328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119017328/doc4.xml","form_type":"4"}},{"id":3608427,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":33975,"kind":"person","name":"Danziger Asaf","position":1,"cik":"0001654435","reported_name":"Danziger Asaf","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2019-03-06T21:17:39.000Z","date":"2019-03-04","kind":"sale","acquired":false,"shares":6127,"price":56.002,"value":343124.254,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 6,127 shares in multiple trades at prices ranging from $55.37 to $56.36.  The price reported above reflects the weighted average sale price.  Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":240198,"source":{"system":"sec-edgar","filing":"0001209191-19-017328","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000120919119017328/doc4.xml","form_type":"4"}}],"next_cursor":"2019-03-06T21:17:39.000000Z,3608427"}